180 related articles for article (PubMed ID: 24633296)
1. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
Kumai T; Ishibashi K; Oikawa K; Matsuda Y; Aoki N; Kimura S; Hayashi S; Kitada M; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2014 May; 63(5):469-78. PubMed ID: 24633296
[TBL] [Abstract][Full Text] [Related]
2. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
3. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
4. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.
Shen L; Schroers R; Hammer J; Huang XF; Chen SY
Cancer Immunol Immunother; 2004 May; 53(5):391-403. PubMed ID: 14624313
[TBL] [Abstract][Full Text] [Related]
5. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
Kobayashi H; Song Y; Hoon DS; Appella E; Celis E
Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551
[TBL] [Abstract][Full Text] [Related]
6. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
[TBL] [Abstract][Full Text] [Related]
7. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
9. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen.
Kobayashi H; Omiya R; Ruiz M; Huarte E; Sarobe P; Lasarte JJ; Herraiz M; Sangro B; Prieto J; Borras-Cuesta F; Celis E
Clin Cancer Res; 2002 Oct; 8(10):3219-25. PubMed ID: 12374692
[TBL] [Abstract][Full Text] [Related]
10. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
13. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
[TBL] [Abstract][Full Text] [Related]
15. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer.
Azumi M; Kobayashi H; Aoki N; Sato K; Kimura S; Kakizaki H; Tateno M
J Urol; 2010 May; 183(5):2036-44. PubMed ID: 20303532
[TBL] [Abstract][Full Text] [Related]
16. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
17. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
18. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
19. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
Zhou G; Ding ZC; Fu J; Levitsky HI
J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518
[TBL] [Abstract][Full Text] [Related]
20. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP.
Kobayashi H; Nagato T; Oikawa K; Sato K; Kimura S; Aoki N; Omiya R; Tateno M; Celis E
Clin Cancer Res; 2005 May; 11(10):3869-78. PubMed ID: 15897588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
